Holen Sie sich die Stockscreener-App
28.07
1.70%
-0.485
Handel nachbörslich:
28.08
0.005
+0.02%
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals (APLS) Stock Moves After Q3 Results - GuruFocus.com
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday - MSN
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month LowTime to Sell? - MarketBeat
Apellis Pharma stock hits 52-week low at $25.31 amid market challenges - Investing.com
Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Apellis stock drops after Q3 miss (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
47,500 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Bought by AlphaCentric Advisors LLC - MarketBeat
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results - The Manila Times
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know - MSN
A Glimpse of Apellis Pharmaceuticals's Earnings Potential - Benzinga
The Latest Analyst Ratings For Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Given Sector Perform Rating at Royal Bank of Canada - MarketBeat
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Previ - GuruFocus.com
Allspring Global Investments Holdings LLC Trims Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Rating Increased to Strong-Buy at Evercore ISI - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Apellis Pharmaceuticals : Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria - Marketscreener.com
What is William Blair's Forecast for APLS Q1 Earnings? - MarketBeat
What is William Blair's Forecast for APLS Q4 Earnings? - MarketBeat
Axonis Therapeutics Announces $115 Million Series A Financing - Quantisnow
Apellis Pharmaceuticals (APLS) to Release Earnings on Tuesday - MarketBeat
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst - Yahoo Finance
2023 Vision Health Report: Post Pandemic Recovery-Challenges Remain - GlobeNewswire Inc.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Short Interest Up 38.2% in October - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Now Covered by Analysts at Royal Bank of Canada - MarketBeat
Assenagon Asset Management S.A. Purchases 1,409,707 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Given New $38.00 Price Target at Mizuho - MarketBeat
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and MaplebearJohnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information - GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results - The Manila Times
Relative Strength Alert For Apellis Pharmaceuticals - Nasdaq
How to Take Advantage of moves in (APLS) - Stock Traders Daily
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stake Lifted by Cwm LLC - MarketBeat
Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt? - Simply Wall St
What is William Blair's Forecast for APLS Q3 Earnings? - MarketBeat
William Blair Initiates Coverage of Apellis Pharmaceuticals (APLS) with Outperform Recommendation - MSN
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch - AOL
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Receives New Coverage from Analysts at Scotiabank - MarketBeat
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN - StockTitan
Dimensional Fund Advisors LP Has $1.29 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals Inc.: Market Leadership & Differentiation of SYFOVRE Driving Our Bullishness!Major Drivers - Smartkarma
Apellis Pharma stock hits 52-week low at $26.67 amid market challenges - Investing.com Australia
Apellis Pharmaceuticals (NASDAQ:APLS) Sets New 1-Year LowTime to Sell? - MarketBeat
(APLS) Trading Report - Stock Traders Daily
The Manufacturers Life Insurance Company Trims Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stake Cut by Mackenzie Financial Corp - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Teachers Retirement System of The State of Kentucky Invests $725,000 in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Apellis falls on potential EU snub for eye therapy (update) - MSN
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):